Loading clinical trials...

COMPLETEDPHASE1

Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

An Open Label, Randomized, 3-Period Crossover Study to Evaluate the Comparative Bioavailability of Variably Aged MK-0974 Capsules Administered Orally as Single Doses in Healthy Male and Female Subjects

NCT01209741•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subject is in good health
•Subject is a nonsmoker
•Subject is willing to comply with the study restrictions

Exclusion Criteria

•Subject has a history of stroke, chronic seizures, or major neurological disorder
•Subject has a history of cancer
•Subject is a nursing mother
•Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study

Key Dates

Start Date

October 1, 2007

Primary Completion Date

November 1, 2007

Completion Date

November 1, 2007

Last Updated

August 18, 2015

Enrollment

ACTUAL participants

Conditions

Migraine

Interventions

telcagepant potassium

DRUG

MK-0974 5Mo5C

DRUG

MK-0974 12Mo5C

DRUG

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Chronic Migraine

View study

RECRUITINGPHASE3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

RECRUITINGNA

Mind Body Balance for Pediatric Migraine

NCT04715685

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 18, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Mind Body Balance for Pediatric Migraine

Light Exposure, Migraine Outcomes, and Sleep Quality

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Prophylactic Treatment With Atorvastatin for Episodic Migraine.